Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 358Carcinoma, Non-Small-Cell Lung 178Neoplasms 109Breast Neoplasms 97Lung Neoplasms 81Urinary Bladder Neoplasms 79Neoplasm Metastasis 74Ovarian Neoplasms 53Cholangiocarcinoma 39Sarcoma 38Lymphoma 38Biliary Tract Neoplasms 35Gallbladder Neoplasms 34Hodgkin Disease 30Lymphoma, Non-Hodgkin 27Adenocarcinoma 27Lymphoma, Large B-Cell, Diffuse 25Colorectal Neoplasms 24Bile Duct Neoplasms 23Triple Negative Breast Neoplasms 22Recurrence 22Fallopian Tube Neoplasms 22Unspecified Adult Solid Tumor, Protocol Specific 21Carcinoma, Transitional Cell 21Carcinoma, Ovarian Epithelial 21Urethral Neoplasms 20Carcinoma 17Adenocarcinoma of Lung 15Head and Neck Neoplasms 14Carcinoma, Renal Cell 14

Interventions

niraparib 1cabozantinib 1avelumab 1Sunitinib 1Paclitaxel 1Gemcitabine 1Everolimus 1Cisplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urothelial Cancer × Gemcitabine × Clear all
NCT00821327 2016-10-25

Gemzar, Cisp, Sunitinib Urothelial Ca

US Oncology Research

Phase 2 Completed
36 enrolled 9 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡